Evaluating the efficacy of neoadjuvant endocrine therapy in HER2-low versus HER2-negative breast cancer

Last Updated: Thursday, September 10, 2026

A retrospective cohort study of 3,808 women evaluated whether HER2-low status is associated with improved clinical response to neoadjuvant endocrine therapy among patients with early-stage HR+ breast cancer. Results showed that age, duration of neoadjuvant endocrine therapy, and HER2 status were significant predictors of any response to neoadjuvant endocrine therapy, supporting the concept of HER2-low disease as a distinct therapeutic entity.

Clinical Breast Cancer

U.S. Food and Drug Administration

FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

Breast Cancer Research Foundation

A revolution in breast cancer prevention is underway—With AI mammogram-based risk assessment starting at 35

Clinical Breast Cancer

Evaluating the efficacy of neoadjuvant endocrine therapy in HER2-low versus HER2-negative breast cancer

Frontiers in Oncology

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer

ESMO Open

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the phase III EMBER-3 trial

Cancers

Body mass index and outcomes in HR+/HER2- metastatic breast cancer treated with palbociclib: Insights from a national real-world study

Journal of Clinical Medicine

Is genetic testing of HER2-negative metastatic breast cancer patients implemented into clinical practice? A retrospective analysis

npj Breast Cancer

Imlunestrant with or without abemaciclib in advanced breast cancer: Safety analyses from the EMBER-3 trial

Breast Cancer Research

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors

Cancer Treatment Reviews

Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis

HR+ HER2- Breast Cancer Resource Center

Evaluating the efficacy of neoadjuvant endocrine therapy in HER2-low versus HER2-negative breast cancer

U.S. Food and Drug Administration

FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

Breast Cancer Research Foundation

A revolution in breast cancer prevention is underway—With AI mammogram-based risk assessment starting at 35

Clinical Breast Cancer

Evaluating the efficacy of neoadjuvant endocrine therapy in HER2-low versus HER2-negative breast cancer

Frontiers in Oncology

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer

ESMO Open

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the phase III EMBER-3 trial

Cancers

Body mass index and outcomes in HR+/HER2- metastatic breast cancer treated with palbociclib: Insights from a national real-world study

Journal of Clinical Medicine

Is genetic testing of HER2-negative metastatic breast cancer patients implemented into clinical practice? A retrospective analysis

npj Breast Cancer

Imlunestrant with or without abemaciclib in advanced breast cancer: Safety analyses from the EMBER-3 trial

Breast Cancer Research

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors

Cancer Treatment Reviews

Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis

Managing Adverse Events for Women Receiving Adjuvant Breast Cancer Treatment

Seeing the Whole Picture: Labs, Circulating Tumor DNA, Imaging, and Clinical Advocacy in the Management of Recurrent HR+ HER2- Breast Cancer

Navigating Treatment Adherence in Early-Stage Breast Cancer